title: [Clinical analysis of salivary malignant pleomorphic adenoma--a report of 95 cases].
abstract: OBJECTIVE
  Malignant pleomorphic adenoma is rare with extensive location, which makes it difficult to evaluate the efficacy of the treatments. This study was to summarize the clinical features of salivary malignant pleomorphic adenoma, and thus to explore the treatment principle and efficacy of the treatment.
  
  
  METHODS
  Clinical data of 95 salivary malignant pleomorphic adenoma patients, treated in Cancer Center, Sun Yat-sen University from May 1970 to Oct. 2000, were analyzed retrospectively. The overall cumulative survival rate was estimated using life table method by SPSS10.0 software. Survival curves were compared with Gehan method.
  
  
  RESULTS
  The 5-, 10-, and 15-year overall survival rates of the 95 patients were (64.9+/-4.9)%, (56.3+/-5.4)%, and (47.8+/-6.1)%, respectively. The 5-and 10-year disease-specific survival rates for the patients received surgery (51 cases), surgery plus radiotherapy (35 cases) were 76.1%, 63.7% and 69.9%, 50.8%, respectively, but the 5-and 10-year disease-specific survival rates for the patients received radiotherapy only, chemotherapy only and radiochemotherapy (4 cases) were all 0.
  
  
  CONCLUSIONS
  Surgery or surgery-dominated multi-modality are the principal treatment modalities for salivary malignant pleomorphic adenoma. The efficacy of surgery and surgery plus radiotherapy is better than non-surgery treatments.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
authors.forename: Zhi-Xing
authors.initials: ZX
authors.lastname: Chen
authors.forename: Quan
authors.initials: Q
authors.lastname: Zhang
authors.forename: Zhu-Ming
authors.initials: ZM
authors.lastname: Guo
authors.forename: Mao-Wen
authors.initials: MW
authors.lastname: Wei
authors.forename: An-Kui
authors.initials: AK
authors.lastname: Yang
mesh_terms: D008949:Adenoma, Pleomorphic / Q000188:drug therapy / Q000628:therapy*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010307:Parotid Neoplasms / Q000628:therapy; D012189:Retrospective Studies; D012468:Salivary Gland Neoplasms / Q000628:therapy*; D013365:Submandibular Gland Neoplasms / Q000628:therapy; D015996:Survival Rate